These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 10550416

  • 1. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats.
    Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X.
    Diabetologia; 1999 Nov; 42(11):1324-31. PubMed ID: 10550416
    [Abstract] [Full Text] [Related]

  • 2. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
    Tajima A, Yamamoto K, Kozakai A, Okumura-Kitajima L, Mita Y, Kitano K, Jingu S, Nakaike S.
    Eur J Pharmacol; 2011 Mar 25; 655(1-3):99-107. PubMed ID: 21262219
    [Abstract] [Full Text] [Related]

  • 3. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.
    Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, Junien JL, Aubert ML.
    Diabetes; 2002 May 25; 51(5):1461-9. PubMed ID: 11978643
    [Abstract] [Full Text] [Related]

  • 4. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.
    Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, Hughes TE, Wang PR.
    J Pharmacol Exp Ther; 2005 Nov 25; 315(2):688-95. PubMed ID: 16027230
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent.
    Takasaki K, Iwase M, Nakajima T, Ueno K, Nomoto Y, Nakanishi S, Higo K.
    Eur J Pharmacol; 2004 Feb 23; 486(3):335-42. PubMed ID: 14985056
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
    Edgerton DS, Johnson KM, Neal DW, Scott M, Hobbs CH, Zhang X, Duttaroy A, Cherrington AD.
    Diabetes; 2009 Jan 23; 58(1):243-9. PubMed ID: 18840785
    [Abstract] [Full Text] [Related]

  • 8. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.
    Lugari R, Dei Cas A, Ugolotti D, Barilli AL, Camellini C, Ganzerla GC, Luciani A, Salerni B, Mittenperger F, Nodari S, Gnudi A, Zandomeneghi R.
    Horm Metab Res; 2004 Feb 23; 36(2):111-5. PubMed ID: 15002062
    [Abstract] [Full Text] [Related]

  • 9. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
    Fukuda-Tsuru S, Anabuki J, Abe Y, Yoshida K, Ishii S.
    Eur J Pharmacol; 2012 Dec 05; 696(1-3):194-202. PubMed ID: 23022337
    [Abstract] [Full Text] [Related]

  • 10. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats.
    Lee Y, Kwon MK, Kang ES, Park YM, Choi SH, Ahn CW, Kim KS, Park CW, Cha BS, Kim SW, Sung JK, Lee EJ, Lee HC.
    J Gene Med; 2008 Mar 05; 10(3):260-8. PubMed ID: 18085721
    [Abstract] [Full Text] [Related]

  • 11. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S, Roy S, Sethi S, Benjamin B, Sundaram S, Khanna V, Kandalkar SR, Pal C, Kant R, Patra AK, Rayasam G, Mittra S, Saini KS, Paliwal J, Chugh A, Ahmed S, Sattigeri J, Cliff I, Ray A, Bansal VS, Bhatnagar PK, Davis JA.
    Eur J Pharmacol; 2011 Feb 10; 652(1-3):157-63. PubMed ID: 20540938
    [Abstract] [Full Text] [Related]

  • 12. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
    Yamazaki K, Yasuda N, Inoue T, Nagakura T, Kira K, Shinoda M, Saeki T, Tanaka I.
    J Pharmacol Exp Ther; 2006 Dec 10; 319(3):1253-7. PubMed ID: 16980568
    [Abstract] [Full Text] [Related]

  • 13. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
    Ahrén B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE.
    Diabetes Obes Metab; 2011 Sep 10; 13(9):775-83. PubMed ID: 21507182
    [Abstract] [Full Text] [Related]

  • 14. DPP-4 inhibition increases GIP and decreases GLP-1 incretin effects during intravenous glucose tolerance test in Wistar rats.
    Freyse EJ, Berg S, Kohnert KD, Heinke P, Salzsieder E.
    Biol Chem; 2011 Mar 10; 392(3):209-15. PubMed ID: 21281062
    [Abstract] [Full Text] [Related]

  • 15. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice.
    Reimer MK, Holst JJ, Ahrén B.
    Eur J Endocrinol; 2002 May 10; 146(5):717-27. PubMed ID: 11980629
    [Abstract] [Full Text] [Related]

  • 16. Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions.
    Pala L, Ciani S, Dicembrini I, Bardini G, Cresci B, Pezzatini A, Giannini S, Mannucci E, Rotella CM.
    Diabet Med; 2010 Jun 10; 27(6):691-5. PubMed ID: 20546289
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N, McClean PL, Flatt PR.
    J Pept Sci; 2007 Jun 10; 13(6):400-5. PubMed ID: 17486662
    [Abstract] [Full Text] [Related]

  • 18. Dipeptidyl peptidase IV inhibitor NVP-DPP728 ameliorates early insulin response and glucose tolerance in aged rats but not in aged Fischer 344 rats lacking its enzyme activity.
    Mitani H, Takimoto M, Kimura M.
    Jpn J Pharmacol; 2002 Apr 10; 88(4):451-8. PubMed ID: 12046989
    [Abstract] [Full Text] [Related]

  • 19. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
    Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Tanaka I.
    Metabolism; 2003 Jan 10; 52(1):81-6. PubMed ID: 12524666
    [Abstract] [Full Text] [Related]

  • 20. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
    Kieffer TJ, McIntosh CH, Pederson RA.
    Endocrinology; 1995 Aug 10; 136(8):3585-96. PubMed ID: 7628397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.